Squarepoint
KLRS

Squarepoint’s Kalaris Therapeutics KLRS Stock Holding History

Squarepoint’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Sell
38,775
-998
-3% -$5.18K ﹤0.01% 4116
2026
Q1 		$229K Buy
39,773
+14,406
+57% +$128K ﹤0.01% 3886
2025
Q4 		$214K Sell
25,367
-14,806
-37% -$94.7K ﹤0.01% 3822
2025
Q3 		$232K Sell
40,173
-18,922
-32% -$62.5K ﹤0.01% 3846
2025
Q2 		$158K Buy
59,095
+44,508
+305% +$201K ﹤0.01% 4050
2025
Q1 		$117K Sell
14,587
-106
-0.7% -$1.04K ﹤0.01% 4181
2024
Q4 		$142K Buy
+14,693
New +$222K ﹤0.01% 4589
2024
Q1 		– Sell
-12,397
Closed -$194K – 4722
2023
Q4 		$194K Buy
12,397
+9,682
+357% +$382K ﹤0.01% 3607
2023
Q3 		$134K Sell
2,715
-1,437
-35% -$97.9K ﹤0.01% 3513
2023
Q2 		$325K Buy
4,152
+954
+30% +$90.7K ﹤0.01% 2918
2023
Q1 		$290K Buy
3,198
+38
+1% +$4.84K ﹤0.01% 2593
2022
Q4 		$373K Buy
+3,160
New +$536K ﹤0.01% 2458
2022
Q3 		– Sell
-738
Closed -$66K – 3541
2022
Q2 		$66K Sell
738
-489
-40% -$51.3K ﹤0.01% 2681
2022
Q1 		$190K Buy
1,227
+562
+85% +$112K ﹤0.01% 2492
2021
Q4 		$198K Buy
+665
New +$308K ﹤0.01% 2708
2021
Q3 		– Sell
-950
Closed -$431K – 3535
2021
Q2 		$431K Buy
+950
New +$491K ﹤0.01% 2253

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's KLRS Position: Q2 2026 in Review

Squarepoint reduced its Kalaris Therapeutics (KLRS) stake by 2.5% in Q2 2026, selling an estimated $5.18K and leaving 38,775 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #4116.

Squarepoint first reported a position in KLRS in Q2 2021 and has held it in 16 quarters since. The position peaked at $431K in Q2 2021. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Squarepoint held 38,775 shares of Kalaris Therapeutics worth $158K as of Q2 2026.
  • Squarepoint sold 998 Kalaris Therapeutics shares in Q2 2026, an estimated $5.18K.
  • Kalaris Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4116 holding.
  • Squarepoint first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Squarepoint's Kalaris Therapeutics position peaked at $431K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.